A new immunomodulatory for multiple sclerosis, Myelimab, mod…
A new immunomodulatory for multiple sclerosis, Myelimab, modulates the immune system, leading to decreased demyelination. It also decreases the number of microglial cells in the brain and increases the chance of viral infection with JCV, a potentially deadly virus. Why would Myelimab increase viral infection probability?
Read Details